Can-Fite BioPharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Can-Fite BioPharma sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Can-Fite BioPharma: 4 sponsored US clinical trials, 1 recruiting.
Can-Fite BioPharma sponsors 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cirrhosis, with 1 trials.
Upper-quartile sponsor footprint
Can-Fite BioPharma sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
NCT05201404
Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)
NCT02128958
Trial of CF101 to Treat Patients With Psoriasis
NCT01265667
Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients
NCT00280917
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Can-Fite BioPharma pipeline
1 recruiting of 4 indexed (25% open); 3 completed (75%).
Phase mix: 1 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Cirrhosis (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Can-Fite BioPharma: open-pipeline peers nationwide
Peers matched on 4 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Can-Fite BioPharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
- Adrienne G. Waks · 25% recruiting · 4 trials
Related
What to do with this Can-Fite BioPharma page
4 registered trials is a research-attention snapshot, not an endorsement of Can-Fite BioPharma or any single study.
- 1 of Can-Fite BioPharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cirrhosis is the condition Can-Fite BioPharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cirrhosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Can-Fite BioPharma pipeline card: 4 registered trials from official public datasets.Report a data error.